---
schema_version: "secwatch.filing_event.v1"
accession: "0001610618-24-000043"
form_type: "8-K"
ticker: null
cik: "0001610618"
company_name: "Cidara Therapeutics, Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T13:59:22.215513+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cidara reports FY2023 net loss $22.9M; effects 1-for-20 reverse stock split

## Summary
- Net loss $22.9M in FY2023 ($33.6M in 2022); revenue $63.9M. Cash $35.8M at Dec 31, 2023.
- 1-for-20 reverse stock split effective April 23, 2024; shares begin trading split-adjusted April 24.
- REZZAYO approved in EU and UK; Cidara received $11.1M and $2.8M milestone payments.
- IND for lead oncology DFC CBO421 expected mid-2024; Phase 3 ReSTORE China data expected Q2 2024.
- Financial results restated to correct understated accrued liabilities and operating expenses from indirect taxes.

## SEC filing metadata
- accession: 0001610618-24-000043
- form_type: 8-K
- cik: 0001610618
- company_name: Cidara Therapeutics, Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/0001610618-24-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/cdtx-20240422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001610618-24-000043
- JSON: https://secwatch.observer/filing/0001610618-24-000043.json
- Plain text: https://secwatch.observer/filing/0001610618-24-000043.txt

## Key facts
- Earnings Releases
  Cidara Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $17.6 million and $63.9 million.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $17.6 million and $63.9 million
  - Result: reported results
  source text: a Top Workplace by The San Diego Union-Tribune for the sixth year, ranking among the top 100 companies. Fourth Quarter and Full Year 2023 Financial Results • Revenue totaled $17.6 million and $63.9 million for the three months and full year ended December 31, 2023, respectively, compared with $10.2 million and $64.4 million for the same periods in 2022. Revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/0001610618-24-000043-index.htm
- Governance Changes
  Cidara Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-20 reverse stock split and reduce authorized shares to 20,000,000 (effective 2024-04-23).
  - Change: charter amendment
  - Effective: 2024-04-23
  source text: On April 22, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-20 reverse stock split of the Company’s outstanding common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000043/0001610618-24-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.